Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triple intrathecal chemotherapy
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intrathecal
01
Overview
Triple Intrathecal Chemotherapy is a combination regimen in which three drugs—methotrexate, cytarabine (also known as cytosine arabinoside), and hydrocortisone—are administered directly into the cerebrospinal fluid (CSF) via lumbar puncture or an Ommaya reservoir. This approach is used for both treatment and prophylaxis of central nervous system (CNS) involvement in cancers such as acute lymphoblastic leukemia (ALL), lymphoma, and leptomeningeal carcinomatosis from solid tumors. Methotrexate and cytarabine are antimetabolite chemotherapeutic agents that inhibit DNA synthesis in rapidly dividing cells, while hydrocortisone is a corticosteroid added to reduce inflammation and lower the risk of chemical meningitis. The combination aims to maximize anti-cancer efficacy within the CNS compartment where systemic chemotherapy penetration is limited[1][2][5][8].
- Brand names
- None
- Other names
- triple intrathecal therapyTITtriple ITC
02
Targets
DHFR (Dihydrofolate reductase)POLA1 (DNA polymerase alpha)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on triple intrathecal chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triple intrathecal chemotherapy.